Replimune Group Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Replimune Group is gedaald met een gemiddeld jaarlijks tempo van -31.4%, terwijl de winst van de sector Biotechs jaarlijks groeide met 7.7%.

Belangrijke informatie

-31.4%

Groei van de winst

-19.1%

Groei van de winst per aandeel

Biotechs Groei van de industrie	-14.6%
Inkomstengroei	n/a
Rendement op eigen vermogen	-55.8%
Nettomarge	n/a
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Opbrengsten en kosten

Hoe Replimune Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

DB:7R8 Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	-213	61	169
30 Jun 24	-220	60	175
31 Mar 24	-216	61	172
31 Dec 23	-210	59	167
30 Sep 23	-199	57	155
30 Jun 23	-182	55	134
31 Mar 23	-174	51	123
31 Dec 22	-157	46	107
30 Sep 22	-147	45	96
30 Jun 22	-133	42	87
31 Mar 22	-118	39	76
31 Dec 21	-108	35	71
30 Sep 21	-100	31	66
30 Jun 21	-91	27	60
31 Mar 21	-81	24	54
31 Dec 20	-75	23	48
30 Sep 20	-70	21	46
30 Jun 20	-61	20	40
31 Mar 20	-53	17	36
31 Dec 19	-43	15	30
30 Sep 19	-35	12	25
30 Jun 19	-30	10	23
31 Mar 19	-31	9	20
31 Dec 18	-31	9	19
30 Sep 18	-28	8	15
30 Jun 18	-26	7	13
31 Mar 18	-20	6	11
31 Dec 17	-17	4	9

Kwaliteitswinsten: 7R8 is momenteel verliesgevend.

Groeiende winstmarge: 7R8 is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 7R8 is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 31.4% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van 7R8 over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: 7R8 is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( -18.2% ).

Rendement op eigen vermogen

Hoge ROE: 7R8 heeft een negatief Return on Equity ( -55.84% ), omdat het momenteel verliesgevend is.

Replimune Group Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Recent updates

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from Ignyte Clinical Trial of Rp1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc 2024)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Executive Chairman recently sold €226k worth of stock

Replimune Group, Inc. Announces Management Changes

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

No longer forecast to breakeven

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

CEO & Director recently sold €298k worth of stock

No longer forecast to breakeven

Insufficient new directors

Replimune Group, Inc. Announces Executive Appointments

Now 23% undervalued

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Replimune Group, Inc. announced that it has received $200 million in funding from Hercules Capital, Inc. and other investors

Replimune Group, Inc., Annual General Meeting, Sep 07, 2022

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 2000 Growth Index

Replimune Group, Inc. Announces the Resignation of Jason Rhodes from Its Board of Directors

Chief Commercial Officer recently sold €150k worth of stock

Replimune Group, Inc. Announces Updated Data from Completed Cohorts of the Phase 2 Part of the IGNYTE Clinical Trial in Non-Melanoma Skin Cancer (Nmsc) and Melanoma

Replimune Group, Inc. Announces Departure of Dr. Otello Stampacchia from its Board of Directors

Now 22% undervalued after recent price drop

Chief Medical Officer Andrea Pirzkall has left the company

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 3000E Index

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1

Forecast to breakeven in 2026

Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma

New 90-day low: €30.40

Replimune Group, Inc. Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

New 90-day high: €41.20

Replimune Group Inc. Announces Poster Presentations at the SITC 2020 Annual Meeting and a Presentation at the SITC 2020 Annual Meeting Virtual Press Conference

New 90-day high: €36.20

Replimune Group, Inc. Appoints Tanya Lewis to its Board of Directors, Effective November 2, 2020

Replimune Group, Inc. Announces Initial Clinical Data of Rp2 and Updated Clinical Data of RP1

New 90-day high - €21.40

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden